Charles River Laboratories (CRL) reported $1.01 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 1.7%. EPS of $2.27 for the same period compares to $2.78 a year ago.The reported revenue represents a surprise of +1.44% over the Zacks Consensus Estimate of $997.24 million. With the consensus EPS estimate being $2.05, the EPS surprise was +10.73%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare ...